Company
STADA
10 published works
Big Molecule Watch
STADA and SBP Group Launch Biosimilars Partnership
STADA and Sino Biopharmaceutical Limited (“SBP Group”), through its subsidiary Chia Tai Tianqing Pharmaceutical Group (“CTTQ”), have entered into a partnership to manufacture, market, and sell biosimilars. CTTQ will develop,…
Big Molecule Watch
European Biosimilar Updates
On February 13, 2026, STADA and Bio-Thera announced that they have received European Marketing Authorization for GOTENFIA®, a golimumab biosimilar to Johnson & Johnson’s SIMPONI®. GOTENFIA® is a human monoclonal…
Big Molecule Watch
European Biosimilar Updates – Alvotech/Advanz’s MYNZEPLI Approval and Bio-Thera/STADA Tocilizumab Alliance
On August 21, 2025, Alvotech and Advanz Pharma Holdco Limited (“Advanz”) announced that MYNZEPLI®, a biosimilar of Regeneron’s EYLEA® (aflibercept), was approved by the European Commission. MYNZEPLI® will be available…
Big Molecule Watch
STADA and Alvotech Announce Launch of UZPROVO® in Europe
By Tara Thigpen
On July 22, 2024, STADA Arzeimittel AG (“STADA”) and Alvotech announced the launch of ustekinumab biosimilar AVT04 under the name UZPROVO® across a majority of European countries. UZPROVO®, the first…
Litigation Finance Journal
SdK Offers Litigation Finance to Enforce Claims for Additional Payment for Former Shareholders of STADA Arzneimittel AG
By John Freund
Former shareholders of STADA Arzneimittel AG who tendered their Stada shares as part of the takeover offer by Nidda Healthcare Holding AG in August or September 2017 are entitled to…
Big Molecule Watch
Alvotech and STADA obtain approval in Europe for ustekinumab biosimilar, UZPRUVO
On January 10, Alvotech announced that the European Commission (EC) issued a marketing authorization to its European commercialization partner, STADA, for UZPRUVO (AVT04), a biosimilar referencing STELARA (ustekinumab). The authorization…
Big Molecule Watch
European Biosimilar Regulatory Updates
By Lihui Bai
STADA and Xbrane Announce Approval of Ranibizumab Biosimilar in UK On January 16, 2023, STADA Arzneimittel AG (STADA) and Xbrane Biopharyma AB (Xbrane) announced that the UK’s Medicines and Healthcare…
Big Molecule Watch
Alvotech Broadens Access to HUMIRA (adalimumab) Biosimilars
By Yoko Bian
Alvotech announced yesterday the launch of HUKYNDRA, a high-concentration, low-volume, citrate-free biosimilar to HUMIRA (adalimumab), in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia. Through a strategic partnership with…
Big Molecule Watch
Alvotech and STADA Launch HUKYNDRA® (Biosimilar of HUMIRA®) in Europe
By Audie Soucy
Alvotech and Stada recently announced the launch of HUKYNDRA® to patients in certain European countries, including France, Germany, Finland, and Sweden. HUKYNDRA® is a biosimilar of HUMIRA® (adalimumab) developed by…
Big Molecule Watch
STADA and Xbrane Ink Commercialization Deal with Bausch + Lomb for LUCENTIS Biosimilar Candidate
On May 6, 2020, Bausch + Lomb and co-development partners STADA and Xbrane announced that they have entered into an exclusive licensing agreement with one another under which Bausch +…